Pipeline and Technology

Compounds

Chakra Biotech has an exclusive world-wide license to six composition of matter patent applications. The chemistry of these compounds present some very novel opportunities to develop first-in-class and best-in-class candidates for psychiatric illnesses. The chemical manufacturing process is also proprietary and facilitates the syntheses of chiral compounds from the start.

Screening a portion of the compounds through Chakra's discovery platform, the chakragati mouse, has identified a pipeline of six leads with significant potential as drugs targeting schizophrenia and depression. We are pushing our lead compound through preclinical development for an IND filing for schizophrenia.

Our approach to drug discovery is the evidence-based approach but using a validated model of schizophrenia. The chakragati mouse has been shown to exhibit several endophenotypes found in schizophrenic patients. We believe an effective therapy needs to modulate an orchestra of targets to equilibrium in such mechanistically complex illnesses. Subsequent to discovering a candidate, we then carry out binding studies to understand the preferred target of action of our candidate.

We are in the process of expanding the number of chemicals synthesized and screening through our neurobehavioral screening facility to identify leads for memory deficits, pain, anxiety and ADHD, to name a few.

“These novel compounds are potentially important new agents because they have been identified through a unique physiologically based transgenic mouse model of dopamine function. This greatly increases the likelihood of success in the clinic and reduces the time needed for successful development. Combining the Central Nervous System drug development experience of Tikvah Therapeutics’ personnel with the novel drug discovery capability of Chakra Biotech forges a strong partnership for advancing new treatments for a number of serious psychiatric and neurological illnesses.” Daniel E. Casey, M.D., Professor of Psychiatry and Neurology, Oregon Health and Science University.

chakragati Mouse Model

Chakra Biotech has a world-wide exclusive license to a mouse model for dopamine dysfunction, validated as a model for screening antipsychotic compounds. This IP asset has been sub-licensed to our spin-off company in Malaysia, Chakra Biotech Sdn Bhd, which is being established to provide contract research services with the chakragati mouse as well as a compendium of other conditioned behavioural models of behaviour.

For more information on the chakragati mouse model or other Chakra Biotech Sdn Bhd screening services please link to Chakra Biotech Sdn Bhd or contact webinfo@chakrabiotech.com.my or